Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform

We found no evidence of a difference in COVID-19 mortality among people who received hydroxychloroquine for treatment of rheumatological disease before the COVID-19 outbreak in England. Therefore, completion of randomised trials investigating pre-exposure prophylactic use of hydroxychloroquine for prevention of severe outcomes from COVID-19 are warranted.

Read the full article here

Source: The Lancet Rheumatology

Categories: Latest Headlines, Rheumatology

Tags: covid19, hydroxychloroquine

Tweets with this article

The Lancet Rheumatology

ICYMI in our January issue— @DarthCTR and colleagues examine the effect of pre-exposure use of #hydroxychloroquine on #COVID19 mortality using data from the @OpenSafely platform https://t.co/lqQ5ShwJ9g Plus linked comment by @AprilJorgeMD https://t.co/eOa8sSatFj https://t.co/HUS03BNKs6

Cardiovascular risk in young people with childhood onset systemic lupus erythematosus

Since 1940, epidemiologists, clinicians, and scientists promoted increased awareness of the crucial importance of promoting preventive strategies for minimising the risk of poor health later…

The Lancet Rheumatology April 26, 2024

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial

Two conventional synthetic DMARD tapering strategies were associated with significantly lower rates of flare-free survival compared with stable conventional synthetic DMARD treatment, and the data…

The Lancet Rheumatology April 25, 2024

A new tool for stratifying children with suspected Sjögren’s disease

Little is known about the natural course and long-term outcomes of childhood-onset Sjögren’s disease due to its low prevalence, difference in clinical presentation between children…

The Lancet Rheumatology April 24, 2024

The Florida Scoring System for stratifying children with suspected Sjögren’s disease: a cross-sectional machine learning study

The Florida Scoring System is a paediatrician-friendly tool that can be used to assist classification and long-term monitoring of suspected childhood Sjögren’s disease. The resulting…

The Lancet Rheumatology April 24, 2024

Debashish Danda

Debashish Danda, professor of rheumatology and immunology at Narayana Health Institute, Bengaluru, India, died on Feb 23, 2024. He had an illustrious career as a…

The Lancet Rheumatology April 24, 2024

Debashish Danda

Debashish Danda, professor of rheumatology and immunology at Narayana Health Institute, Bengaluru, India, died on Feb 23, 2024. He had an illustrious career as a…

The Lancet Rheumatology April 23, 2024

The Lancet Rheumatology Home Page

Explore clinical research, expert reviews, and comment and opinion from The Lancet Rheumatology. A voice for rheumatology specialists worldwide

The Lancet Rheumatology April 23, 2024

A preoperative package of care for osteoarthritis, consisting of weight loss, orthotics, rehabilitation, and topical and oral analgesia (OPPORTUNITY): a two-centre, open-label, randomised controlled feasibility trial

Participants adhered well to the non-operative interventions and their health-related quality of life improved. Participant and health professional feedback were extremely positive. These findings support…

The Lancet Rheumatology April 22, 2024

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials

In patients where antidrug antibodies were detected, remission was less likely to be reached and sustained, and infusion reaction or discontinuation of infliximab was more…

The Lancet Rheumatology April 19, 2024

CAR T-cell therapy for SLE in children

On March 11, 2024, Seattle Children’s Hospital (Seattle, WA, USA) announced that it had received approval from the US Food and Drug Administration for a…

The Lancet Rheumatology April 18, 2024

Related Articles